Skip to main content

Table 2 Pharmacokinetic parameters and PK/PD target attainment of vancomycin in critically ill patients

From: Does contemporary vancomycin dosing achieve therapeutic targets in a heterogeneous clinical cohort of critically ill patients? Data from the multinational DALI study

Parameter

All patients (n = 42)

Intermittent dosing (n = 18)

Continuous infusion (n = 24)

P *

Vancomycin dose (mg/kg)

27 [18 - 32]

27 [22 - 30]

27 [17 - 33]

0.611

Elimination rate constant (h -1 )**

0.09 [0.03 - 0.13]

0.09 [0.03 - 0.13]

-

-

Clearance (L/h)

3.6 [1.9 - 5.9]

5.1 [2.4 - 7.1]

2.7 [1.7 - 4.1]

0.038

Half-life (h) **

8.2 [5.4 - 24.1]

8.2 [5.4 - 24.1]

-

-

C min (mg/L)

17 [8 - 23]

10 [7- 17]

21 [14 - 26]

0.029

C min ≥15 mg/L, n (percentage)

24 (57.1)

7 (38.9)

17 (70.8)

0.038

AUC 0–24 /MIC

655 [368 - 911]

409 [246 - 712]

830 [529 - 952]

0.029

AUC 0–24 /MIC > 400, n (percentage)

30 (71.4)

9 (50.0)

21 (87.5)

0.008

Length of vancomycin therapy on sampling date

    

 Days, n

4 [1 - 7]

2 [1 - 6]

4 [1 - 7]

0.314

 >2 days, n (percentage)

23/41 (56.1)

8/18 (44.4)

15/23 (65.2)

0.183

 >3 days, n (percentage)

22/41 (53.7)

8/18 (44.4)

14/23 (60.9)

0.295

  1. Data are described as median [1st - 3rd quartile] or n (%). For pharmacodynamics calculations, an MIC of 1 mg/L was assumed. *Indicates difference between intermittent dosing and continuous infusion of vancomycin; **could only be determined in patients receiving intermittent dosing. Cmin, minimum concentration of drug observed during the dosing period; AUC0–24/MIC, ratio of the area under the concentration-time curve over a 24-hour period divided by the minimum inhibitory concentration of the suspected bacteria.